HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Glenmark Pharma’s arm to launch Sodium Bicarbonate Injection USP
Nov-04-2025

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., (Glenmark) is all set to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark’s 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA. Glenmark will begin distribution in November 2025.

According to IQVIA sales data for the 12-month period ending August 2025, the 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately $63.8 million. Glenmark’s 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


  RELATED NEWS >>